Dogmas, challenges, and promises in phase III allergen immunotherapy studies

Dogmas, challenges, and promises in phase III allergen immunotherapy studies

The concept of treatment of an allergy with the offending allergen was introduced more than a century ago. Allergen immunotherapy (AIT) is the only disease modifying treatment of allergic diseases caused by inhalational allergens and insect venoms. Despite this, only few AIT products have reached li...

Full description

Bibliographic Details
Main Authors: Pieter-Jan De Kam, PhD, Matthias F. Kramer, MD, Mohamed H. Shamji, PhD, Kemi Oluwayi, MD, Matthew D. Heath, PhD, Erika Jensen-Jarolim, MD, Markus H. Berger, MD, Uwe E. Berger, MBA, Anke Graessel, PhD, Fiona Sellwood, Stefan Zielen, MD, Christian Vogelberg, MD, Petra Zieglmayer, MD, Ralph Mösges, MD, PhD, Ludger Klimek, MD, PhD, Lawrence M. DuBuske, MD, Wayne G. Shreffler, MD, PhD, Jonathan A. Bernstein, MD, Thomas M. Kündig, MD, Murray A. Skinner, PhD
Format: Article
Language:English
Published: Elsevier 2021-09-01
Series:World Allergy Organization Journal
Subjects:
Allergen immunotherapy
Phase III
Placebo effect
Biomarker
Blinding
Online Access:http://www.sciencedirect.com/science/article/pii/S1939455121000727

Internet

http://www.sciencedirect.com/science/article/pii/S1939455121000727

Similar Items